All BioNTech articles
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
OpinionA rough guide to pharma partnership deals
Coronavirus vaccines are driving unusual collaborations with a range of benefits
-
BusinessPfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
-
BusinessOxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
BusinessModerna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
-
OpinionA promising peep at Covid-19 vaccine efficacy
Pfizer–BioNTech’s will need to be one of many if we are to overcome the pandemic
-
BusinessEarly indications suggest Pfizer–BioNTech’s Covid-19 vaccine is effective
Company claims 90% efficacy at preventing disease, but experts call for data rather than press releases
-
BusinessEncouraging signs from initial Covid-19 vaccine trials
Human trials deliver positive immune responses, while primate challenge studies suggest protection is possible
-
BusinessRNA vaccines are coronavirus frontrunners
Several groups have potential Sars-CoV-2 vaccines ready or close to testing, thanks to rapid development pathways